Brief: Biogen Says Biologics License Application For Subcutaneous Formulation Of Leqembi For Treatment Of Early Alzheimer’S Disease Designated For Priority Review In China
09/02/2026 02:05
Feb 8 (Reuters) - Biogen BIIB.O: BIOGEN: BIOLOGICS LICENSE APPLICATION FOR SUBCUTANEOUS FORMULATION OF LEQEMBI FOR TREATMENT OF EARLY ALZHEIMER’S DISEASE DESIGNATED FOR PRIORITY REVIEW IN CHINA Source text: https://tinyurl.com/ye2b3au3 Further company coverage: 4523.T ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biogen
See all newsHealth Rounds: Old cancer drug may help restore fertility for certain women
U.S. STOCKS ON THE MOVE-FactSet, Moderna, Goldman Sachs
U.S. STOCKS ON THE MOVE-Biogen, Incyte, Quantum Cyber
Biogen rises; co scales back drug programs acquired through $5.6 bln Apellis deal
Biogen scales back Apellis programs, trims research roles after $5.6 billion buyout